Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson
Topics & Concepts
TrametinibDabrafenibMedicineInternal medicineClinical endpointLung cancerAdverse effectPopulationOncologyPhases of clinical researchMEK inhibitorResponse Evaluation Criteria in Solid TumorsCancerClinical trialGastroenterologyVemurafenibMAPK/ERK pathwayMetastatic melanomaBiologyKinaseEnvironmental healthCell biologyMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsSynthesis and biological activity